EU approves CSL Behring's Privigen for CIDP

04/8/2013 | Pharmaceutical Business Review Online

The European Commission granted CSL Behring approval to market Privigen, an intravenous immune globulin, as a treatment for chronic inflammatory demyelinating polyneuropathy. Positive results from the Privigen Impact on Mobility and Autonomy trial were cited in the application.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ